Literature DB >> 1331062

Cleavage specificity on synthetic peptide substrates of human rhinovirus 2 proteinase 2A.

W Sommergruber1, H Ahorn, A Zöphel, I Maurer-Fogy, F Fessl, G Schnorrenberg, H D Liebig, D Blaas, E Kuechler, T Skern.   

Abstract

Proteinase 2A of human rhinovirus serotype 2 (HRV2 2A) was expressed in Escherichia coli and partially purified; the preparation was used to study various enzymatic parameters. Using a 16-amino acid peptide representing the native cleavage region of HRV2 2A, an apparent Km value of 5.4 x 10(-4) mol/liter was determined. A minimum of 9 amino acids (comprising residues P8 to P1') was necessary for cleavage to occur. Proteolysis of substituted peptides was highly tolerant toward changes at P1, P2', and P3' but an absolute requirement for glycine P1' and a high preference for threonine P2 was found. Furthermore, HRV2 2A only cleaved peptide substrates derived from other rhinovirus serotypes and poliovirus that possessed P2 Thr and P1' Gly. Thus, the sequence Thr-X-Gly may form the basis of the cellular cleavage site processed by rhinoviral 2As during viral replication. Studies with various inhibitors support the hypothesis that HRV2 2A belongs to a new class of cysteine proteinases.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1331062

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  38 in total

1.  Ex vivo and in vivo inhibition of human rhinovirus replication by a new pseudosubstrate of viral 2A protease.

Authors:  Nisrine Falah; Sébastien Violot; Didier Décimo; Fatma Berri; Marie-Laure Foucault-Grunenwald; Théophile Ohlmann; Isabelle Schuffenecker; Florence Morfin; Bruno Lina; Béatrice Riteau; Jean-Claude Cortay
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

2.  Selective Removal of FG Repeat Domains from the Nuclear Pore Complex by Enterovirus 2A(pro).

Authors:  Nogi Park; Nicholas J Schweers; Kurt E Gustin
Journal:  J Virol       Date:  2015-08-26       Impact factor: 5.103

3.  Cleavage of Poly(A)-binding protein by coxsackievirus 2A protease in vitro and in vivo: another mechanism for host protein synthesis shutoff?

Authors:  V Kerekatte; B D Keiper; C Badorff; A Cai; K U Knowlton; R E Rhoads
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

4.  Dual inhibition of human rhinovirus 2A and 3C proteases by homophthalimides.

Authors:  Q M Wang; R B Johnson; L N Jungheim; J D Cohen; E C Villarreal
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

5.  Differential processing of nuclear pore complex proteins by rhinovirus 2A proteases from different species and serotypes.

Authors:  Kelly Watters; Ann C Palmenberg
Journal:  J Virol       Date:  2011-08-10       Impact factor: 5.103

6.  Human rhinovirus 2A proteinase mutant and its second-site revertants.

Authors:  M Luderer-Gmach; H D Liebig; W Sommergruber; T Voss; F Fessl; T Skern; E Kuechler
Journal:  Biochem J       Date:  1996-08-15       Impact factor: 3.857

7.  3C-like protease of rabbit hemorrhagic disease virus: identification of cleavage sites in the ORF1 polyprotein and analysis of cleavage specificity.

Authors:  C Wirblich; M Sibilia; M B Boniotti; C Rossi; H J Thiel; G Meyers
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

8.  Inhibition of U snRNP assembly by a virus-encoded proteinase.

Authors:  Laura L Almstead; Peter Sarnow
Journal:  Genes Dev       Date:  2007-05-01       Impact factor: 11.361

9.  Bidirectional increase in permeability of nuclear envelope upon poliovirus infection and accompanying alterations of nuclear pores.

Authors:  George A Belov; Peter V Lidsky; Olga V Mikitas; Denise Egger; Konstantin A Lukyanov; Kurt Bienz; Vadim I Agol
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

10.  Conformational plasticity of the 2A proteinase from enterovirus 71.

Authors:  Qixu Cai; Muhammad Yameen; Weihua Liu; Zhenting Gao; Yaozong Li; Xuanjia Peng; Yaxian Cai; Caiming Wu; Qian Zheng; Jian Li; Tianwei Lin
Journal:  J Virol       Date:  2013-04-24       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.